Author details

Full Name

Jonathan T Lei

Affiliation

ORCID

Career Start Year

2007

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37501682	Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment.	Cancer Res Commun	2023
37587913	Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins.	Cancer Res Commun	2023
37619559	A proteogenomics data-driven knowledge base of human cancer.	Cell Syst	2023
36711982	Deep learning prediction boosts phosphoproteomics-based discoveries through improved phosphopeptide identification.	bioRxiv	2023
37137501	The Breast Cancer Proteome and Precision Oncology.	Cold Spring Harb Perspect Med	2023
37390209	Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness.		2023
37071495	Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.	Cancer Res	2023
36619972	Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach.	iScience	2022
36105216	Epithelial immunomodulation by aerosolized Toll-like receptor agonists prevents allergic inflammation in airway mucosa in mice.	Frontiers in Pharmacology	2022
36001024	Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer.	Cancer Discov	2022
35418131	LINC00355 regulates p27<sup>KIP</sup> expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer.	NPJ Breast Cancer	2022
36258226	Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness.	Breast Cancer Res	2022
34711608	Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.	Cancer Res	2021
33767418	Proteogenomics drives therapeutic hypothesis generation for precision oncology.	Br J Cancer	2021
33417831	Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma.	Cancer Cell	2021
32142667	Neurofibromin Is an Estrogen Receptor-Î± Transcriptional Co-repressor in Breast Cancer.	Cancer Cell	2020
31099189	Copy number alterations associated with clinical features in an underrepresented population with breast cancer.	Molecular genetics & genomic medicine	2019
31839155	Endocrine therapy resistance: new insights.	Breast	2019
31106278	alterations and metastasis in estrogen receptor positive breast cancer.	Journal of Cancer Metastasis and Treatment	2019
29748621	Proteomic profiling identifies key coactivators utilized by mutant ERÎ± proteins as potential new therapeutic targets.	Oncogene	2018
30498031	DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer.	Proc Natl Acad Sci U S A	2018
30525098	fusions drive endocrine therapy resistance and metastasis in breast cancer.	Molecular and Cellular Oncology	2018
30089255	Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.	Cell Rep	2018
28801307	Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.	Cancer Discov	2017
26977876	Mammary Ductal Environment Is Necessary for Faithful Maintenance of Estrogen Signaling in ERâº Breast Cancer.	Cancer Cell	2016
27251275	Proteogenomics connects somatic mutations to signalling in breast cancer.	Nature	2016
21965659	Three lysine residues in the common Î² chain of the interleukin-5 receptor are required for Janus kinase (JAK)-dependent receptor ubiquitination, endocytosis, and signaling.	Journal of Biological Chemistry	2011
18511572	Separate endocytic pathways regulate IL-5 receptor internalization and signaling.	Journal of Leukocyte Biology	2008
18955567	Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRalpha gene in the X chromosome pseudoautosomal region 1.	J Exp Med	2008
17227823	JAK kinases control IL-5 receptor ubiquitination, degradation, and internalization.	Journal of Leukocyte Biology	2007